routinely, a bolus of 5.000-10.000 iu human chorionic gonadotropin (hcg) is usedfor the final follicular maturation and ovulation as a standard method. hcg has thesame effect of luteinizing hormone (lh) with long half-life. it has the longlutheotrophic effect which increases the risk of ovarian hyper stimulation syndrome(ohss). recently, gonadotropin-releasing hormone agonist (gnrh-a) trigger h...

It is estimated that around 55-60% of men with prostate cancer will develop metastatic disease, most commonly involving bone. The initial treatment for metastatic disease is hormonal ablation, either with surgery (bilateral orchidectomy) or medically with gonadotrophin releasing hormone analogues such as goserelin, leuprorelin or triptorelin. A luteinising hormone-releasing hormone (LHRH) antag...

BACKGROUND In view of the current debate concerning possible differences in efficacy between the two GnRH analogues used in IVF stimulated cycles, the current study aimed to explore whether progesterone control in the late follicular phase differs when GnRH antagonist is used as compared with GnRH agonist, and if so, to what extent the progesterone rise affects the probability of pregnancy. M...

BACKGROUND Although initial studies in poor responders using GnRH antagonists have reported encouraging results, they are limited in number, only a few of them are prospective, while the majority is characterized by limited power to detect a clinically important difference. METHODS A randomized controlled trial was performed in patients with one or more previous failed IVF cycles in which fiv...

A synthetic analog of gonadoliberin (gonadtropin-releasing factor of luteinizing hormone/follicle-stimulating hormone-releasing hormone), designated A-43818, was evaluated for its ability to effect regression of carcinogen-induced mammary tumors in the Sprague-Dawley rat. This analog, specifically (D-leuyl6, desglycyl-NH210, prolyl ethylamide9), gonadoliberin, is a potent synthetic luteinizing ...

Introduction: Gonadotropin-releasing hormone (GnRH) agonist triggers are increasingly used in antagonist vitro fertilization (IVF) cycles to prevent ovarian hyperstimulation syndrome (OHSS) following a robust response. The luteolytic effects of GnRH agonists inhibit implantation or spontaneous pregnancy, warranting freezing available blastocysts for future transfer after the risk OHSS subsides....